# Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

> **NCT00281580** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1461 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Amlodipine 5 mg
- **DRUG:** Placebo
- **DRUG:** Telmisartan 20 mg
- **DRUG:** Telmisartan 40 mg
- **DRUG:** Amlodipine 10 mg
- **DRUG:** Telmisartan 20 mg
- **DRUG:** Telmisartan 80 mg
- **DRUG:** Amlodipine 10 mg
- **DRUG:** Telmisartan 20 mg
- **DRUG:** Amlodipine 5 mg
- **DRUG:** Amlodipine 5 mg
- **DRUG:** Telmisartan 20 mg
- **DRUG:** Amlodipine 5 mg
- **DRUG:** Amlodipine 5 mg
- **DRUG:** Amlodipine 2.5 mg
- **DRUG:** Amlodipine 2.5 mg
- **DRUG:** Amlodipine 10 mg
- **DRUG:** Amlodipine 2.5 mg
- **DRUG:** Telmisartan 80 mg
- **DRUG:** Telmisartan 80 mg

## Key facts

- **NCT ID:** NCT00281580
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-03
- **Final completion:** —
- **Target enrollment:** 1461 (ACTUAL)
- **Last updated:** 2014-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00281580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00281580, "Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00281580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*